tion between putamen influx (Ki) and clinical rating, but not symptom duration. In 11 patients with hemi-Parkinson's disease of recent onset there were significant differences between normal (mean 0-0123 (SD 0.0023)), asymptomatic (mean 0 0099 (0.0020)) and symptomatic (mean 0*0070 (00.014)) putamen Kis A group of normal unrelated controls (n = 16, mean age 63 (SD 13)) were recruited and scanned over the same period. Patients were deemed to have unilateral Parkinson's disease if they scored zero on one side for UPDRS and if all timed tests for this limb fell within 1 SD of the mean time for that from a larger group (including most of the scanned controls) of normal subjects (n = 23, mean age 63 (SD 12)).
All subjects gave written informed consent before PET. Permission to perform these studies was obtained from the ethics committee of the Hammersmith Hospital, London, United Kingdom, and from the Administration of Radioactive Substances Advisory Committee, United Kingdom.
All subjects were given carbidopa-100 mg one hour before and 50 mg five minutes before scanning. When available we introduced the catechyl-o-methyl transferase inhibitor entacapone"3 (Orion Farmos pharmaceuticals) and 14 of the 27 patients with Parkinson's disease and eight of the 16 normal subjects were given 400 mg and two other normal subjects were given 800 mg entacapone orally one hour before scanning. PET was performed using the CTI 931/08/12 tomograph (CTI, Knoxville, TN) with a protocol of 31 time frames over 93 minutes. ['5F]dopa MBq) in 10 ml normal saline solution was infused intravenously over 30 seconds. A radial arterial line gave plasma counts and samples for metabolite analysis using alumina extraction. 14 Data In each of the 11 patients with clinically unilateral Parkinson's disease, identified as above, the putamen Ki contralateral to the affected limb was lower than that of the ipsilateral putamen. There was a significant difference (P < 0 05, Mann-Whitney U test) between the mean putamen Ki of the normal group (0-0123 (SD 0 0023)) and the mean putamen Ki ipsilateral to the affected limb (0-0099 (SD 0-0020)). There was also a significant difference (P < 0-005, Mann-Whitney U test) between the mean putamen Ki ipsilateral and contralateral (0 0070 (SD 0.014)) to the affected limbs. Figure 1 shows the individual results for the putamen ipsilateral and contralateral to the affected limb.
A discriminant function completely separated the normal and Parkinson's disease ['8F]dopa PET results. Figure 2 shows the discriminant scores and separation of the groups. There was a significant correlation (r = -0-49, P = 0-01, Spearmnan rank correlation) between discriminant score and total UPDRS score. There was no significant difference between the discriminant scores of those with unilateral and those with bilateral symptomatology. When the discriminant function from a previous study 9 was applied to this group four patients with Parkinson's disease were incorrectly assigned to the normal group.
Discussion
The extent of disease at the onset of clinical symptomatology is an issue crucial to understanding the disease process in Parkinson's disease. When this group of 27 patients with early Parkinson's disease was considered the mean putamen Ki was 62% of normal but this group contains patients of varying disease severity and duration. The 11 patients with unilateral symptomatology represent the earliest clinical stage of the disease. If the right and left putamen deteriorate and produce clinical signs independently then this group allows us to study both early clinical disease in the putamen contralateral to the affected limb and preclinical disease in the putamen contralateral to the unaffected limb. Our estimate for the mean threshold putamen ['8F]dopa uptake, at which symptoms develop, is between 57% and 80% of normal (as this group had symptoms for a mean of two years before scanning the true threshold is unlikely to be as low as 57%). The results from the putamen contralateral to the symptomatic limb lay between 41% and 89% of the normal mean, with only two results lying within 2 SDs. By contrast [18F]dopa uptake measured in the presymptomatic putamen ranged between 60% and 127% of the normal mean, nine of the 11 results lying within 2 SDs.
We have previously used ['8F]dopa PET to try to identify preclinical disease in at risk relatives,'7 but only one of these to date has gone on to develop unequivocal Parkinson's disease. The means and SDs from the normal and presymptomatic groups presented here allow assessment of the implication of a single putamen result (assuming a normal distribution around the mean in each). Below a putamen Ki of 0 0077 min-' (two SDs below the normal mean) lie 2-5% of normal putamen results; only 15% of presymptomatic putamen results in our unilateral Parkinson's disease group would fall below this point. Hence most subjects with genuine preclinical disease are likely to have putamen Ki results within 2 SDs of the normal mean. Either they do not have the disease or it is not identifiable with this technique. The incidence of incidental Lewy body disease (suggested to be the pathological precursor of Parkinson's disease) has been estimated at 3-8% in the sixth decade rising to 12-8% in the ninth decade.'0 Consequently a putamen Ki with a value falling two SDs below the normal mean in a subject from the general population is still more likely to be normal than to represent preclinical disease.
If putamen Ki is proportional to nigral cell count2 then our study suggests that at symptom presentation in unilateral Parkinson's disease the cell count on the preclinical side is still in the normal range in most patients classified as Hoehn and Yahr score 1. We are not aware of postmortem data from patients with very recent onset of disease. Bernheimer et all first identified severe dopamine depletion at symptom onset in Parkinson's disease but the average duration of disease in their patients with idiopathic parkinsonism was 9 3 (SD 5 7) years. Several postmortem studies'8-20 found nigral cell counts reduced by between 60% and 70% in Parkinson's disease but only considered patients with severe disease. Our findings are in keeping with the calculations of Feamley and Lees21 who studied a group of patients with a more recent onset of symptoms (although only two patients, each Hoehn and Yahr grade 3, had disease onset of less than five years). They computed a short preclinical period (4 7 years), an age adjusted total nigral cell count of 69% at presentation, and an exponential deterioration in cell count. Given the expected progression from unilateral to bilateral disease in a mean six years,6 putamen Ki values for the asymptomatic side would be expected to be much closer to those measured for the symptomatic side if the preclinical period were more prolonged.
Of course [18F]dopa uptake is not a measure of nigrostriatal cell count, but of presynaptic dopaminergic terminal function. It is possible that a depleted cell pool is able to compensate by upregulation of putamen dopa decarboxylase activity, maintaining both clinical normality and ['8F]dopa uptake. Such a mechanism could explain the lack of an aging effect on normal striatal function reported in some PET studies2223 and would make our conclusion about a short preclinical period for Parkinson's disease less secure.
We were able to show an inverse correlation between UPDRS scores and putamen
[58F]dopa uptake but there was no correlation between performance on our quantitative tests and ['8F]dopa uptake in the contralateral putamen (even when a subgroup taking selegiline was excluded). Decline in motor performance is probably related to fall in [18F]dopa uptake from the premorbid value in each person rather than any absolute value and the spread of measured ['5F]dopa uptake in normal subjects is wide. There was no significant correlation between putamen [18F]dopa uptake and duration of symptoms. This is not surprising given the lack of correlation between duration of symptoms and clinical rating, and is compatible with the lack of correlation between duration of disease and severity of nigral cell loss previously reported. ' To test discriminant analysis at the earliest stages of disease we applied it to this group of patients and normal subjects. The groups were again completely separated and discrimination was equally effective for patients with unilateral and bilateral symptomatology. We then applied the discriminant function obtained by Sawle et al.9 Four of the 27 patients were misclassified, emphasising that discriminant analysis is of greater value as a descriptive than a predictive test.
This study shows an apparent wide difference in side to side putamen ['8F]dopa uptake in unilateral Parkinson's disease, with ipsilateral putamen function often normal. This suggests a relatively short preclinical period. Either true preclinical disease is difficult to detect with this technique (and subjects previously suspected as having preclinical disease may simply represent the lower end of a wide normal range) or the ipsilateral putamen is unaffected at this stage. Morphological and biochemical data from patients with recent onset unilateral disease are required to determine whether thepreservation of function that we find in the asymptomatic putamen is due to absence of disease, biochemical compensation, or insensitivity of the technique.
